Mankind Pharma

    MANKIND
    Pharma
    ₹2280.00
    price as of 11/9/2026, 5:28:07 pm

    Market cap ₹94,174 Cr

    P/E
    46.09
    Day range
    ₹2,222.00 – ₹2,280.00
    52-week range
    ₹1,909.70 – ₹2,674.00
    Volume
    5.31 L
    Open
    ₹2,237.20
    Prev close
    ₹2,238.40
    52-week range, adjusted for splits and bonuses
    ₹1,909.7₹2,674
    23 Mar 202622 Sept 2025
    Index membership & F&O
    NIFTY 200NIFTY 500NIFTY MIDCAP 150NIFTY HEALTHCARENIFTY PHARMAF&O lot 250

    Price history

    6M change +1.61%RSI (14) 37.5 NeutralSMA 20 · 50 overlaid

    Price & delivery on the exchange

    NSE bhavcopy to 11 Sept 2026 · delivery 71.5% today vs 53.4% average · BSE close ₹2,277

    1 Apr23 Apr15 May5 Jun24 Jun15 Jul3 Aug21 Aug11 Sept₹1,750₹2,000₹2,250₹2,500₹2,7500%25%50%75%100%
    • Delivery
    • NSE close
    • BSE close

    High delivery with a rising price suggests buyers holding rather than trading the move.

    Futures & options

    NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

    Short covering
    Near-month future
    ₹2,281.2
    Change
    +1.49%
    Basis over spot
    +₹1.28
    Futures OI (shares)
    27.4 L
    OI change
    -2.25%
    Put-call ratio
    0.78
    Max pain
    ₹2,340
    Resistance (call OI)
    ₹2,400
    Support (put OI)
    ₹2,200
    Lot size
    250

    Open interest by strike

    Calls open above (resistance) and puts below (support), in shares

    1920202020802140220022602320238024402500256026202680065,0001.3 L1.9 L2.6 Lspot
    • Call OI
    • Put OI

    Futures open interest and price

    Near-month future, day by day since collection began

    The daily history builds from each close.

    Key metrics

    P/E (TTM)
    45.5
    EPS (TTM)
    ₹49.42
    ROE (FY26)
    12.7%
    ROCE (latest year)
    14%

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +17.7%
    Profit 3Y CAGR
    +13.9%
    Revenue YoY (Jun 2026)
    +12.9%
    Profit YoY (Jun 2026)
    +29.0%
    Operating margin
    26.0%
    Net margin
    14.2%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 20260 Cr1.5K Cr3.0K Cr4.5K Cr6.0K Cr0%7%14%21%28%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • Promoter
    • DII
    • FII
    • Public

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-13.0KCr-6.5K Cr0 Cr6.5K Cr13.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr4.5K Cr9.0K Cr13.5K Cr18.0K Cr0.0x0.1x0.3x0.5x0.6x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales2,7082,6072,4222,8683,0613,1993,0793,5703,6973,5673,4434,031
    Expenses2,0252,0001,8362,1962,2142,3832,3962,7242,7762,6482,5132,974
    Operating Profit6836065866728478166838479219199301,056
    OPM %25%23%24%23%28%26%22%24%25%26%27%26%
    Other Income637594108109872498394-319449
    Interest999117221191171170157142110
    Depreciation96110100103100187231219222223223226
    Profit before tax641562572666849495511540624509659769
    Tax %20%18%17%18%22%22%17%18%17%19%15%25%
    Net Profit511460477543659385425445520414559574
    EPS in Rs₹12.51₹11.33₹11.76₹13.39₹16.31₹9.22₹10.20₹10.62₹12.39₹9.90₹13.43₹13.75

    From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Strengths, risks & growth

    Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. [1]

    Strengths

    • Company has reduced debt.

    Risks

    • Promoter holding has decreased over last 3 years: -3.87%

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +18%
    3 Years
    +18%
    TTM
    +14%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +11%
    3 Years
    +17%
    TTM
    +13%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    +9%
    1 Year
    -12%

    Return on Equity

    10 Years
    —
    5 Years
    +17%
    3 Years
    +16%
    Last Year
    +13%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter72.67%72.66%72.66%72.63%-0.03 pp
    FII12.83%11.34%10.24%9.45%-0.79 pp
    DII11.91%13.26%14.46%15.39%+0.93 pp
    Public2.57%2.75%2.63%2.53%-0.10 pp

    Filed with NSE for Jun 2026: promoters 72.63%, public 27.37% · XBRL filing

    Analysts & fund holdings

    75%
    75% recommend buy
    16 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E46.1 vs 46.4
    Sector P/B5.84

    Who holds the shares, quarter by quarter

    Mutual funds 10.87% (+0.51 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters72.6%
    • Foreign institutions9.4%
    • Mutual funds10.9%
    • Insurance1.5%
    • Other domestic institutions3.0%
    • Retail1.3%
    • Others1.2%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    SBI Large Cap Fund1.00%1.79%-0.10 pp
    Nippon India Growth Mid Cap Fund0.96%1.81%+0.04 pp
    HDFC Large Cap Fund0.67%1.66%-0.13 pp
    Nippon India Large Cap Fund0.47%0.86%+0.02 pp
    Aditya Birla SL Flexi Cap Fund0.43%1.47%-0.11 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1 Per Share

      8 Aug 2025
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Please find attached intimation of participation in the Investor Conferences

    Company Update
    Update On Voluntary Liquidation Of WOS

    Please find attached update on voluntary liquidation of Bharat Serums and Vaccines Limited, a wholly owned subsidiary company.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Please find attached intimation regarding allotment of 49,112 equity shares pursuant to ESOP Plan

    Company Update
    Update On Disinvestment

    Please find attached final update on sale of stake of Broadway Hospitality Services Private Limited, a wholly owned subsidiary company.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Please find attached intimation regarding completion of term of Independent Director

    Company Update
    Announcement under Regulation 30 (LODR)-Restructuring

    Please find attached outcome of the Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limited, a wholly ....

    Others
    Board Meeting Outcome for Dated August 26, 2026

    Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly ....

    Company Update
    Intimation Regarding ESG Rating

    Please find attached intimation regarding ESG Rating

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Please find attached press release dated August 20, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Please find attached Newspaper Advertisement of Notice of Postal Ballot

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    Please find attched postal ballot notice

    Company Update
    Completion Of Realignment Of Security Cover In Respect Of Non-Convertible Debentures And Consequent Release Of Pledged Shares Of Bharat Serums And Vaccines Limited

    Completion of realignment of Security Cover in respect of Non-Convertible Debentures.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Updates on Acquisition

    Please find attached intimation regarding incorporation of a wholly owned subsidiary company in Netherlands

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Please find attached intimation regarding appointment of Mr. Anish Vanraj Bafna as Additional Director designated as Non-Executive Independent Director

    Filed with BSE (scrip 543904); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 24 Jan 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.